A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants

• DOI: 10.1128/mbio.02473-21
• Publication Date: 2021-10-05T08:34:41Z
• Authors: Denise Haslwanter; M. Eugenia Dieterle; Anna Z. Wec; Cecilia M. O’Brien; Mrunal Sakharkar; Catalina Florez; Karen Tong; C. Garrett Rappazzo; Gorka Lasso; Olivia Vergnolle; Ariel S. Wirchnia...; Robert H. Bortz; Ethan Laudermilch; J. Maximilian Fels; Amanda Mengotto; Ryan J. Malonis; George I. Georgiev; Jose A. Quiroz; Daniel Wrapp; Nianshuang Wang; Kathryn E. Dye; Jason Barnhill; John M. Dye; Jason S. McLellan; Johanna P. Daily; Jonathan R. Lai; Andrew S. Herbert; Laura M. Walker; Kartik Chandran; Rohit K. Jangra
• Keywords: 0301 basic medicine; SARS-CoV-2; COVID-19; Microbiology; Antibodies, Neutralizing; QR1-502; 3. Good health; 03 medical and health sciences; Neutralization Tests; Mutation; RNA-Binding Motifs; Humans; Research Article

The U.S. FDA has issued emergency use authorizations (EUAs) for multiple investigational monoclonal antibody (MAb) therapies for the treatment of mild to moderate COVID-19.